Web-based Survey on the Occurrence of Emotional Blunting and Treatment Needs in Japanese Patients with Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Registration Number
- JPRN-UMIN000048497
- Lead Sponsor
- Takeda Pharmaceutical Company Ltd.
- Brief Summary
Of 3376 patients with major depressive disorder included in this study, 67.1% of patients self-reported EB symptoms. The mean (SD) ODQ total score was 78.2 (21.5), which increased with worsening EB symptoms. There were correlations between ODQ total scores and the PHQ-9, GAD-7, WSAS, and EQ-5D-5L scores. Descriptive analyses showed that one-third of patients reporting EB symptoms did not tell their physician, with two-thirds finding these symptoms distressing and likely to affect recovery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3376
Not provided
The preliminary web-based questionnaire ask whether any of the following conditions are met, and those who meet the conditions are not eligible for the survey. (1) Those who have been diagnosed with bipolar disorder. (2) Those who have been diagnosed and are under treatment for serious progressive physical illnesses such as cancer and heart failure.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence ratio of Emotional Blunting (EB) in Japanese patients with major depressive disorder
- Secondary Outcome Measures
Name Time Method 1. The scores of Oxford Depression Questionnaire (ODQ) 2. Correlation between severity of EB (ODQ) and severity of depressive symptoms (PHQ-9: Patient Health Questionnaire-9), or anxiety symptoms (GAD-7: Generalized Anxiety Disorder-7), social functioning (WSAS: Work and Social Adjustment Scale), QOL (EQ-5D-5L) 3. Patient's perception for EB 4. Treatment need for EB